Strive to be the most admired provider of clinical and bioanalytical services in India to support in Pharmaceutical Company's efforts in research and development.

Quality Policy
AnaCipher Clinical Research Organisation will strive to be the most admired provider of clinical and bioanalytical services in India to support national and international efforts in pharmaceutical research and development. AnaCipher Clinical Research Organisation is committed to strict adherence to all applicable guidelines and regulations towards protection of rights and safety of study subjects and generation of high-quality data. This quality policy reflects Indoco Remedies' mission "To improve the quality of life by making available products of highest quality at affordable prices." It will achieve this policy by compliance to quality management systems, continual improvement approach, development of competent workforce, and considering stakeholders as partners in our progress.

Safety Health and Environmental Policy
AnaCipher CRO is committed to:

  1. Demonstrate its commitment to excellence in Safety, Health and Environment (SHE). SHE policy promotes research work in a manner that protects the safety and health of its personnel and the public.
  2. Give priority to SHE in the planning and execution of all research work and related activities of the organisation work towards achieving and maintaining compliance with all relevant and applicable state/central/international regulations; and
  3. Provide training to all personnel on SHE in their respective areas of work.


  AnaCipher CRO receives BE study approval from WHO in March 2020, through a desk assessment review process. The review process involved the Clinical & Bio-analytical phases of the study.
   Indoco's CRO – AnaCipher receives EIR from USFDA
   Indoco's Clinical Research Organisation receives zero 483s from USFDA
   Indoco's CRO – ANACIPHER clears USFDA inspection with ZERO 483
  Conducted internal training on “21 CFR Part 11” on 19th Jul 2019.
  Conducted external training on “ICH-GCP” on 29th Jul 2019